Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FT819
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fate Therapeutics gets RMAT Tag for FT819 in Treating Systemic Lupus Erythematosus
Details : FT819 is the first-ever, off-the-shelf, iPSC-derived CAR T-cell therapy, which is currently being evaluated for the treatment of moderate to severe active systemic lupus erythematosus.
Product Name : FT819
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 14, 2025
Lead Product(s) : FT819
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fate Therapeutics Treats First Lupus Patient in Phase 1 Study of FT819 CAR T-Cell Program
Details : FT819 is the first-ever, off-the-shelf, iPSC-derived CAR T-cell therapy, which is currently being evaluated for the treatment of moderate to severe active systemic lupus erythematosus.
Product Name : FT819
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 05, 2024
Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fate Therapeutics Initiates Phase 1 Trial for FT825 / ONO-8250 in Advanced Solid Tumors
Details : ONO-8250 (FT825) is a multiplexed-engineered CAR T-cell candidate targeting HER2, under Phase 1 trials for HER2-expressing advanced solid tumors.
Product Name : ONO-8250
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 01, 2024
Fate Therapeutics Prices $100 Million Underwritten Offering and Private Placement
Details : The Company plans to use net proceeds to fund clinical trials and nonclinical studies of its candidates, including FT576, an investigational CAR NK cell cancer immunotherapy.
Product Name : FT576
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 19, 2024
Lead Product(s) : FT522,Cyclophosphamide,Rituximab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fate Presents FT522 Preclinical Data for Autoimmune Diseases At ASGCT
Details : FT522 is an iPSC-derived CAR NK cell targeting CD19 with ADR technology, under evaluation for relapsed/refractory B-cell lymphoma.
Product Name : FT522
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 05, 2024
Lead Product(s) : FT522,Cyclophosphamide,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FT576,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $3,100.0 million
Deal Type : Termination
Details : FT576 (CAR NK cells) is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line. FT576 incorporates a proprietary CAR that targets BCMA, a novel high-affinity 158V and non-cleavable CD16 (hnCD16) F...
Product Name : FT576
Product Type : Cell and Gene therapy
Upfront Cash : $100.0 million
May 01, 2023
Lead Product(s) : FT576,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $3,100.0 million
Deal Type : Termination
Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT819 is an investigational, universal, off-the-shelf, T-cell receptor (TCR)-less CD19 chimeric antigen receptor (CAR) T-cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line.
Product Name : FT819
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 12, 2022
Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FT536
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FT536 also incorporates a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; an IL-15 receptor fusion (IL-15RF) that augments...
Product Name : FT536
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 01, 2022
Lead Product(s) : FT536
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ONO-8250
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the Collaboration and Option Agreement, the parties will jointly develop and commercialize FT825 (ONO-8250) in the U.S. and Europe, and ONO maintains exclusive development and commercialization rights for FT825 (ONO-8250) in the rest o...
Product Name : FT825
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : ONO-8250
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : With this agreement, the discovery of iPSC-derived CAR-NK cell therapy will be added to iPSC-derived CAR-T cells therapy for solid tumors. And, a second new target for solid tumor collaboration has been added and ONO will provide Fate with antibodies tha...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Expanded Collaboration